

PATENT



Case 3376/1

RECEIVED
FEB 03 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

FEDDE ET AL

SERIAL NO.: 09/941,206

FILED: 28 August 2001

GROUP ART UNIT: 1614

EXAMINER: M. Benton

DATE: January 28, 2003

TITLE: USE OF AN ALDOSTERONE RECEPTOR ANTAGONIST TO IMPROVE COGNITIVE FUNCTION

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97-1.98**

Commissioner of Patents and Trademarks
Washington, D.C. 20231
Sir:

This Supplemental Information Disclosure Statement is filed pursuant to 37 CFR 1.97-1.98 and MPEP §609. The present Information Disclosure Statement, supplements the Information Disclosure Statement being filed herewith simultaneously. Any fee required by 37 CFR 1.97-1.98 should be charged to Deposit Account No. 19-1025.

This newly cited document is as pertinent as the documents previously cited in this prosecution.

Respectfully submitted,

Joseph R. Schuh
Agent for Applicants
Registration No. 48,180
(314) 274-8182 (St. Louis)

Pharmacia Corporation
Corporate Patent Department
PO Box 1027
Chesterfield, MO 63006



Sheet 1 of 1

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 3376/1	APPLICATION NO.: 09/941,206
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT		INVENTOR: Fedde, et al.	
(Use several sheets if necessary)		Filed: 8/28/01	Group: 1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner Initial		
	C1	Saunders, Francis J & Alberti, Robert L, <i>Aldactone Spironolactone</i> , Searle Laboratories, Chicago, IL

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

(Form PTO-1449)

1614

CERTIFICATE OF MAILING BY FIRST CLASS MAIL (37 CFR 1.8)

Applicant(s): Fedde et al

Docket No.

3376/1/US

Serial No.
09/941,206

Filing Date
08/28/01

Examiner
M. Benton

Group Art Unit
1614

Invention: Use of an Aldosterone Receptor Antagonist to Improve Cognitive Function



RECEIVED
FEB 03 2003
TECH CENTER 1600/2900

I hereby certify that this Transmittal Letter for IDS, Postcard, & Supplemental IDS
(Identify type of correspondence)

is being deposited with the United States Postal Service as first class mail in an envelope addressed to: The
Assistant Commissioner for Patents, Washington, D.C. 20231 on 01/28/03
(Date)

Michelle R. Harber

(Typed or Printed Name of Person Mailing Correspondence)

(Signature of Person Mailing Correspondence)

Note: Each paper must have its own certificate of mailing.